Curcumin in Combination with Other Adjunct Therapies for Brain Tumor Treatment: Existing Knowledge and Blueprint for Future Research
International Journal of Molecular and Cellular Medicine, ISSN: 2251-9645, Vol: 10, Issue: 3, Page: 163-180
2021
- 9Citations
- 13Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations9
- Citation Indexes9
- Captures13
- Readers13
- 13
Article Description
Malignant brain tumors proliferate aggressively and have a debilitating outcome. Surgery followed by chemoradiotherapy has been the standard procedure of care since 2005 but issues of therapeutic toxicity and relapsestill remain unaddressed. Repurposing of drugs to develop novel combinations that can augment existingtreatment regimens for brain tumors is the need of the hour. Herein, we discuss studies documenting the use ofcurcumin as an adjuvant to conventional and alternative therapies for brain tumors. Comprehensive analysis ofdata suggests that curcumin together with available therapies can generate a synergistic action achieved throughmultiple molecular targeting, which results in simultaneous inhibition of tumor growth, and reduced treatmentinducedtoxicity as well as resistance. The review also highlights approaches to increase bioavailability andbioaccumulation of drugs when co-delivered with curcumin using nano-cargos. Despite substantial preclinicalwork on radio-chemo sensitizing effects of curcumin, to date, there is only a single clinical report on braintumors. Based on available lab evidence, it is proposed that antibody-conjugated nano-curcumin in combinationwith sub-toxic doses of conventional or repurposed therapeutics should be designed and tested in clinical studies.This will increase tumor targeting, the bioavailability of the drug combination, reduce therapy resistance, andtumor recurrence through modulation of aberrant signaling cascades; thus improving clinical outcomes in brainmalignancies
Bibliographic Details
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know